Practical Considerations for Demonstrating Drug Substance Uniformity - The authors describe considerations and best practices for meeting drug substance uniformity. - BioPharm International

ADVERTISEMENT

Practical Considerations for Demonstrating Drug Substance Uniformity
The authors describe considerations and best practices for meeting drug substance uniformity.


BioPharm International
Volume 24, Issue 4, pp. 30-37

Tolerance interval

This approach may be used if adequate historical filtration data exists to calculate a tolerance interval and capture the expected long-term behavior of the DS fill process. Typically, the tolerance interval contains 99% of the population (coverage) with a 95% confidence limit. However, the confidence and population coverage depends on the size of the historical data set. Care should be taken in combining data from laboratory or pilot scale filtrations with full–scale or manufacturing data, as the non-recoverable volume of the systems may result in substantial differences in terms of batch uniformity. Additionally, the calculated uniformity limits should not be wider than the DS/DP specification limits. While this method is based on actual historical experience, it does require additional sampling and testing during clinical lots.

Equivalency acceptance criteria

The objective of the equivalency approach is to test the null hypothesis of non-equivalence (non-uniformity) within a DS batch. If the null hypothesis is rejected, evidence of uniformity within a batch is demonstrated. Multiple samples are required for each sample point within the batch, and the means are calculated for each sample location. Uniformity within a batch is demonstrated when proscribed confidence intervals (typically at 90% or 95%) of the difference between the means are within the calculated acceptance criteria. The benefit of this equivalence acceptance criteria (EAC) approach is a statistically defined proof of uniformity within the allowable variability. However, this method does require a larger number of samples to be collected from each sample point in order to have sufficient statistical power to make the acceptance criteria meaningful.

–EAC<1 – 2<EAC
–EAC<1 – 3<EAC
–EAC<2 – 3<EAC

where:

1, 2, 3 are the mean of the sample test parameter over the course of bulk filtration (e.g. protein concentration at the beginning, middle and end), and EAC is the equivalency acceptance criteria. It is beyond the scope of this paper to describe equivalence testing; References 2 and 3 provide general sources on statistical equivalence.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
USP Center in Ghana Receives International Lab Accreditation
August 15, 2014
USP Awards Analytical Research
August 15, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
Guilty Plea to Importing Illegal Cancer Drugs
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here